The $710M preliminary Q3 sales figure is a key top-line data point for a single-product company. Watch for the full Q3 2026 financial filing (expected on Form 20-F or 6-K) for gross profit split with Janssen, operating expense detail, and any guidance update. Consensus estimates for Q3 2026 CARVYKTI sales are not provided in this filing, so the magnitude of beat/miss relative to expectations is unknown.
Price Chart
Executive Summary
Legend Biotech announced preliminary Q3 2026 net trade sales of approximately $710 million for CARVYKTI, its only approved product. The figure is unaudited and provided by partner Janssen. This is a material revenue update for a single-product biotech, but the filing lacks prior-period comparables or consensus context.
Key Facts
- CARVYKTI generated approximately $710 million in net trade sales for Q3 2026 (quarter ended September 30, 2026).
- Sales figure provided by Janssen; Legend Biotech has not independently verified it.
- Data is preliminary and unaudited; final revenue/gross profit determination subject to completion of financial statements.
- Filing is a 6-K (foreign private issuer report) with no other material disclosures.
Financial Impact
Approximately $710 million in net trade sales for CARVYKTI in Q3 2026; no prior-period or consensus comparison provided.
Risk Factors
- Sales figure is preliminary, unaudited, and provided by partner Janssen without independent verification.
- No prior-period or consensus comparison provided; the absolute number alone does not indicate growth trajectory.
- Final revenue recognition and gross profit allocation subject to completion of financial statements and audit.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006593 |
| Document: 0001171843-26-006593-index-headers.html | 0001171843-26-006593 |
| Document: 0001171843-26-006593-index.html | 0001171843-26-006593 |
| Document: 0001171843-26-006593.txt | 0001171843-26-006593 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $20.25 (+2.25%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $20.25 (+13.23%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.25 (+7.57%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.25 (+5.94%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.25 (+5.94%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.25 (+14.57%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.25 (+9.26%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.25 (−7.26%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.25 (−5.06%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.25 (+5.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers